A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BI 1015550 OVER AT LEAST 52 WEEKS IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (PF-ILDS)
- Registry ID
- 1305-0023
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- BOEHRINGER INGELHEIM (CANADA) LTD LTEE
- Start date
- 2023-01-13
- Completion date
- 2025-03-18
- Last update
- 2022-09-15
Conditions
- LUNG DISEASE
- PULMONARY FIBROSIS
Related clinical trials
- A PHASE IIB STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AZD8965 IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (ARGINAUT)
- A MULTINATIONAL, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF SUBJECTS WHO HAVE PARTICIPATED IN AVALYN PHARMA STUDIES OF INHALED ANTIFIBROTIC AGENTS (AP-LTE-008 [SAIL])
- A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF ENV-101 IN PATIENTS WITH LUNG FIBROSIS (WHISTLE-PF TRIAL)
- AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH FIBROTIC LUNG DISEASE
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B STUDY EVALUATING THE SAFETY AND EFFICACY OF PIRFENIDONE SOLUTION FOR INHALATION
(AP01) IN SUBJECTS WITH PROGRESSIVE PULMONARY FIBROSIS (PPF)
- REDUCING RESPIRATORY SYMPTOMS OF PULMONARY IRRADIATION IN INTERSTITIAL LUNG DISEASE (RESPIRE-ILD): A 2X2 FACTORIAL RANDOMIZED PHASE II TRIAL TESTING N-ACETYL CYSTEINE AND DEXAMETHASONE
View on source registry